rent beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. RESPONSE GENETICS, INC.CONDENSED CONSOLIDATED BALANCE SHEETSDecember 31,June 30,20112012Cash and cash equivalents$
1,700,295$
2,562,262Accounts receivable, net 4,047,0594,022,555Prepaid expenses and other current assets991,351639,044Total current assets6,738,7057,223,861Property and equipment, net1,067,6791,157,657Intangible assets44,42399,477Total assets$
7,850,807$
8,480,995Accounts payable$
1,492,526$
1,203,525Accrued expenses and other current liabilities3,251,2621,912,657Other liabilities1,390,1811,318,182Common stock classified outside of stockholders' equity (deficit)7,854,68210,925,724Total stockholders' equity (deficit)(6,137,844)(6,879,093)Total liabilities, common stock classified outside of stockholders' equity (deficit) and stockholders' equity (deficit)$
7,850,807$
8,480,995
The condensed consolidated balance sheet at December 31, 2011 is derived from the audited consolidated financial statements at the date included in the Company's Form 10-K for the fiscal year ended December 31, 2011. The condensed consolidated balance sheet at June 30, 2012 is derived from the unaudited financial statements included in the Company's Form 10-Q for the
'/>"/>
SOURCE Response Genetics, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database2.
NDIA, NTSA Will Be On Hand At Seventh Annual Capitol Hill Modeling and Simulation Expo, Set To Focus On Homeland Security, First Response3.
Bode Technology Launches Same-Day DNA Service For Faster Response to Law Enforcement and Justice System4.
Covenant Security Services and the Department of Homeland Security Partner to Provide Nationwide Training on Active Shooter Awareness and Response5.
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer6.
US Lab Deployed to Boost Mexicos Response to Outbreaks of Infectious Disease7.
Targeted antibacterial agent rapidly created in response to serious food safety pathogen8.
Fukushima 1 year on: Poor planning hampered Fukushima response9.
Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses10.
Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)11.
"O-Shot™" May Improve Female Sexual Response